Is Amazon Stock Still Worth Staking On?
Amazon.com Inc (NASDAQ: AMZN) posted one of its strongest years…
Sell
17
IART Quote, Financials, Valuation and Earnings
Last price:
$22.50
Seasonality move
:
3.33%
Day range:
$22.21 - $22.75
52-week range:
$16.81 - $35.49
Dividend yield:
0%
P/E ratio:
70.14x
P/S ratio:
1.08x
P/B ratio:
1.12x
Volume:
1.1M
Avg. volume:
704.8K
1-year change:
-38.44%
Market cap:
$1.7B
Revenue:
$1.6B
EPS (TTM):
-$0.09
Analysts' Opinion
-
Consensus RatingIntegra Lifesciences Holdings has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 6 Hold ratings, and 2 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $26.25, Integra Lifesciences Holdings has an estimated upside of 16.72% from its current price of $22.49.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 100% downside risk from its current price of $22.49.
Fair Value
-
According to the consensus of 9 analysts, Integra Lifesciences Holdings has 16.72% upside to fair value with a price target of $26.25 per share.
IART vs. S&P 500
-
Over the past 5 trading days, Integra Lifesciences Holdings has overperformed the S&P 500 by 0.12% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Integra Lifesciences Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Integra Lifesciences Holdings has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Integra Lifesciences Holdings reported revenues of $442.6M.
Earnings Growth
-
Integra Lifesciences Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Integra Lifesciences Holdings reported earnings per share of $0.25.
Enterprise value:
3.3B
EV / Invested capital:
0.98x
Price / LTM sales:
1.08x
EV / EBIT:
62.34x
EV / Revenue:
2.03x
PEG ratio (5yr expected):
--
EV / Free cash flow:
217.59x
Price / Operating cash flow:
115.38x
Enterprise value / EBITDA:
16.90x
Gross Profit (TTM):
$882.1M
Return On Assets:
-0.17%
Net Income Margin (TTM):
-0.43%
Return On Equity:
-0.45%
Return On Invested Capital:
-0.21%
Operating Margin:
8.05%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.6B | $1.5B | $1.6B | $397M | $442.6M | |
| Gross Profit | $970.3M | $884.7M | $882.1M | $226.5M | $249.1M | |
| Operating Income | $238.9M | $111.5M | $28.4M | $36M | $35.6M | |
| EBITDA | $381.8M | $256M | $193.3M | $73.6M | $79.1M | |
| Diluted EPS | $2.16 | $0.83 | -$0.09 | $0.25 | $0.25 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.2B | $1.2B | $1.2B | $1.1B | $1.1B | |
| Total Assets | $3.6B | $3.8B | $3.9B | $3.8B | $4B | |
| Current Liabilities | $401M | $340M | $320.9M | $307M | $922.1M | |
| Total Liabilities | $2.1B | $2.1B | $2.1B | $2.2B | $2.5B | |
| Total Equity | $1.5B | $1.7B | $1.8B | $1.6B | $1.5B | |
| Total Debt | $1.6B | $1.5B | $1.4B | $1.5B | $1.8B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $264.5M | $140M | $129.4M | $58.8M | $50.7M | |
| Cash From Investing | -$58.6M | -$94.2M | -$390.8M | -$57.2M | -$4.2M | |
| Cash From Financing | -$252M | -$229.9M | $237.9M | -$6.9M | -$7.2M | |
| Free Cash Flow | $217.4M | $73.1M | $15M | $34.2M | $11.2M | |
IART
Sector
Market Cap
$1.7B
$39.2M
Price % of 52-Week High
63.37%
45.93%
Dividend Yield
0%
0%
Shareholder Yield
-0.41%
-0.81%
1-Year Price Total Return
-34.68%
-38.63%
Beta (5-Year)
1.229
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$22.58
200-day SMA
Sell
Level
$23.61
Bollinger Bands (100)
Sell
Level
21.51 - 25.17
Chaikin Money Flow
Buy
Level
45.8M
20-day SMA
Sell
Level
$22.68
Relative Strength Index (RSI14)
Sell
Level
46.24
ADX Line
Buy
Level
13.41
Williams %R
Neutral
Level
-63.8842
50-day SMA
Sell
Level
$23.75
MACD (12, 26)
Sell
Level
-0.35
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Neutral
Level
38M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.2364)
Sell
CA Score
(Annual)
Level (-0.6994)
Buy
Beneish M-Score
(Annual)
Level (-2.6087)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-4.8767)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Stock Forecast FAQ
In the current month, IART has received 1 Buy ratings 6 Hold ratings, and 2 Sell ratings. The IART average analyst price target in the past 3 months is $26.25.
-
Where Will Integra Lifesciences Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Integra Lifesciences Holdings share price will rise to $26.25 per share over the next 12 months.
-
What Do Analysts Say About Integra Lifesciences Holdings?
Analysts are divided on their view about Integra Lifesciences Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Sell. However, a smaller subset of analysts suggest that Integra Lifesciences Holdings is a Buy and believe this share price will drop from its current level to $35.00.
-
What Is Integra Lifesciences Holdings's Price Target?
The price target for Integra Lifesciences Holdings over the next 1-year time period is forecast to be $26.25 according to 9 Wall Street analysts, 1 of them rates the stock a Buy, 2 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is IART A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Integra Lifesciences Holdings is a Hold. 6 of 9 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of IART?
You can purchase shares of Integra Lifesciences Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Integra Lifesciences Holdings shares.
-
What Is The Integra Lifesciences Holdings Share Price Today?
Integra Lifesciences Holdings was last trading at $22.50 per share. This represents the most recent stock quote for Integra Lifesciences Holdings. Yesterday, Integra Lifesciences Holdings closed at $22.49 per share.
-
How To Buy Integra Lifesciences Holdings Stock Online?
In order to purchase Integra Lifesciences Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Palantir a Good Stock to Buy?
Palantir Technologies (PLTR) stock soared to its highest level in…
Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
